EC Number   |
Activating Compound |
Reference  |
|---|
   3.5.3.18 | D-histidine |
activating ability in decreasing order: histamine, imidazole, L-histidine, D-histidine |
652188 |
| 3.5.3.18 | histamine |
activating ability in decreasing order: histamine, imidazole, L-histidine, D-histidine |
652188 |
| 3.5.3.18 | imidazole |
activating ability in decreasing order: histamine, imidazole, L-histidine, D-histidine |
652188 |
| 3.5.3.18 | L-histidine |
activating ability in decreasing order: histamine, imidazole, L-histidine, D-histidine |
652188 |
| 3.5.3.18 | more |
type of buffer dramatically influences enzyme activity, activity in imidazole/HCl buffer is about 25% higher than in phosphate buffer |
652188 |
| 3.5.3.18 | more |
probucol and the intracellular antioxidant pyrrolidine dithiocarbamate significantly attenuate inhibition of endothelial DDAH activity by oxidized-low density lipoprotein or lysophosphatidylcholine, but probucol or PDTC itself had no effect on the activity of DDAH |
668175 |
| 3.5.3.18 | more |
mRNA expression levels of DDAH-I are not changed in pioglitazone-treated rats |
668890 |
| 3.5.3.18 | visfatin |
mRNA and protein expression of DDAH2 upregulated after 24 h stimulation of visfatin |
697549 |
| 3.5.3.18 | adiponectin |
- |
697831 |
| 3.5.3.18 | all-trans-retinoic acid |
1.9fold increase in DDAH-2 mRNA and protein expression |
697831 |
